

Pre-Prostate Biopsy Rectal Swab Report



Patient Information

Report, Sample

Age/Sex: **34/M**
DOB: **01/01/1990**

Physician Information

Dr. FARGAHI, SIMA
EmeritusDX - Internal Testing
12 Spectrum Pointe Drive
Lake Forest, CA 92630
Phone : 949.418.7225
Fax : 949.418.7287

Sample Information

Accession#: **PB24-00095**
Date Collected: **02/25/2024**
Date Received: **02/26/2024**
Date Reported: **02/26/2024**
Specimen: **Rectal Swab**
ICD 10: **123.45**

Results: **Positive**

ORGANISM(S) - DETECTED

- | | | | |
|-------------------------|-----|-----------------------------------|-----|
| • Escherichia coli | 99% | • Viridans Group Streptococci**** | <1% |
| • Klebsiella pneumoniae | 1% | • Enterococcus faecalis | <1% |

Report Key

RGD = Resistance Gene(s)
Detected

S = Sensitivity Detected

R = Resistance Detected

N = No Reference

	Cefixime	Ciprofloxacin	Doxycycline	Sulfamethoxazole/Trimethoprim	Tobramycin	Cefotaxime	Ceftriaxone	Cefazolin	Cefepime	Cefoxitin	Ceftazidime / Avibactam	Piperacillin / Tazobactam	Cefaclor	Imipenem	Meropenem	Nitrofurantoin	Ofloxacin	Amikacin	Aztreonam	Gentamicin	Tetracycline	Levofloxacin	Amoxicillin / Clavulanate	Ampicillin	Vancomycin	Penicillin G
Formulation	PO	PO/IV	PO/IV	PO/IV	IM/IV	IM/IV	IM/IV	IV	IV	IV	IV	IV	PO	IV	IV	PO	PO	IV/IM	IM/IV	IM/IV	IM/IV	IM/IV	IM/IV	IM/IV	IM/IV	IM/IV
Sensitivity result:																										
Enterococcus faecalis	S	S	S	S	S	S	S	S	S	S	S	S	S	N	N	R	R	R	R	R	S	R	R	R	S	S
Escherichia coli	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	N	S	S	S	R	R
Klebsiella pneumoniae	S	S	S	S	S	S	S	S	S	S	S	S	N	S	S	S	S	S	S	S	R	R	R	R	R	R
Resistant Gene result :	RGD		RGD	RGD		RGD	RGD	RGD		RGD			RGD	RGD	RGD				RGD		RGD			RGD		RGD
Organism(s) Tested-Detected: + = Plus marks are supportive data and are NOT patient specific																										
Enterococcus faecalis			+									+		+		+		+				+	+	+	+	+
Escherichia coli	+	+			+	+	+	+	+	+	+	+		+	+	+	+	+	+	+		+	+			
Klebsiella pneumoniae	+	+		+	+	+	+	+	+	+	+	+		+	+	+	+	+	+	+		+	+			
Viridans Group Streptococci****	+		+			+	+	+	+		+	+	+	+	+							+	+		+	

Information about the table:

Green PlusMarks **+** indicate there is supportive evidence that the antibiotic either FDA approved or off label can be used for treatment. PlusMark treatment options are not intended to be prescriptive for any specific patient. Appropriate judgement should be exercised by the attending physician before prescribing a course of treatment. N = No reliable antibiotic reference is available for the detected organism. **If an organism is listed in the detected section but not reflected in the sensitivity result table, the organism is either fastidious or failed to grow in vitro and cannot be tested for antibiotic susceptibility.**

PHENOTYPIC SENSITIVITY DETECTED: Amikacin(IV/IM), Amoxicillin / Clavulanate(PO), Ampicillin(PO/IV), Aztreonam(IM/IV), Cefaclor(PO), Cefazolin(IV), Cefepime(IV), Cefixime(PO), Cefotaxime(IM/IV), Cefoxitin(IV), ceftazidime-avibactam(IV), Ceftriaxone(IM/IV), Ciprofloxacin(PO/IV), Doxycycline(PO/IV), Gentamicin(IM/IV), Imipenem(IV), Levofloxacin(PO/IV), Meropenem(IV), Nitrofurantoin(PO), Ofloxacin(PO), Penicillin G(IV), Piperacillin / Tazobactam(IV), Sulfamethoxazole/Trimethoprim(PO/IV), Tetracycline(PO), Tobramycin(IM/IV), Vancomycin(IV)

PHENOTYPIC RESISTANCE DETECTED: Amikacin(IV/IM), Amoxicillin / Clavulanate(PO), Ampicillin(PO/IV), Aztreonam(IM/IV), Gentamicin(IM/IV), Levofloxacin(PO/IV), Nitrofurantoin(PO), Ofloxacin(PO), Penicillin G(IV), Tetracycline(PO), Vancomycin(IV)

ANTIBIOTIC RESISTANCE GENES DETECTED: Extended-Spectrum-β-Lactamase*, Sulfonamides Resistance, Tetracycline Resistance

ANTIBIOTIC RESISTANCE GENES NOT DETECTED: Vancomycin Resistant (Glycopeptic antibiotics) , Methicillin Resistance, Quinolone and Fluoroquinolone Resistance, Carbapenem Resistance

• Testing performed at 524 E Elm St Conshohocken, PA 19428 | Medical Director: Joshua Cantor M.D.



CLIA#: 05D2223424
Medical Director: Sima Fargahi M.D.
12 Spectrum Pointe Drive Lake Forest, CA 92630



CLIA#: 39D2071808
Medical Director: Joshua Cantor M.D.
524 E Elm St Conshohocken, PA 19428

Pre-Prostate Biopsy Rectal Swab Report

Patient Name
Report, Sample

Accession Number
PB24-00095

Procedure Date
02/25/2024

ORGANISM(S) - NOT DETECTED

Bacteria: Acinetobacter baumannii, Actinobaculum schaalii, Aerococcus urinae, Alloscardovia omnicolens, Citrobacter freundii, Citrobacter koseri, Coagulase negative Staphylococcus**, Corynebacterium riegelii, Enterobacter aerogenes***, Enterobacter cloacae, Enterococcus faecium, Klebsiella oxytoca, Morganella morganii, Mycoplasma hominis, Pantoea agglomerans, Proteus mirabilis, Proteus vulgaris, Providencia stuartii, Pseudomonas aeruginosa, Serratia marcescens, Staphylococcus aureus, Streptococcus agalactiae, Ureaplasma urealyticum

FUNGUS: Candida albicans, Candida auris, Candida glabrata, Candida parapsilosis

References:

* Extended Spectrum Beta-Lactamase (ESBL) Resistant genes identified confers resistance across multiple classes of antibiotics including Penicillin derivatives, cephalosporins, monobactams and carbapenems. Refer to the "Resistant Gene Detected" row to identify antibiotics for which the resistance gene may impact. Different ESBLs resistant genes will impact different beta lactam antibiotics in different levels and it is considered in the "Resistant Gene Detected" row for both ESBL (extended-spectrum β -lactamase) and BSBL (broad-spectrum β -lactamase).

** Coagulase Negative Staphylococcus includes Staphylococcus saprophyticus, Staphylococcus epidermidis, Staphylococcus haemolyticus.

*** Klebsiella aerogenes (formerly known as Enterobacter aerogenes)

**** Viridans Streptococci group includes Streptococcus anginosus, Streptococcus oralis and Streptococcus pasteurianus, Streptococcus mitis.

Methodology and Clinical Significance: Laboratory utilizes PCR amplification for the targeted detection of the specified organisms. Detected organisms are reported based on their percentage to the total detected organisms. Detected resistance genes are shown as RGD (Resistance Gene Detected) in the report table. In addition, phenotypic antibiotic susceptibility results are ascertained for the detected organism(s) by employing disk diffusion as a reference method for susceptibility. Antibiotic susceptibility testing is not performed for yeasts or fastidious organisms. For full methodology visit www.emeritusdx.com/methodology.

Disclaimer: This test was developed and its performance characteristics determined by laboratory. It has not been cleared or approved by the US Food and Drug Administration. The FDA has determined that such clearance or approvals is not necessary. This test is used for clinical purposes. It should not be regarded as investigational or for research. This laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) as qualified to perform high complexity clinical testing.

Final Report signed by Aan Attaelmanan on 02/26/2024 at 11:43 AM

• Testing performed at 524 E Elm St Conshohocken, PA 19428 | Medical Director: Joshua Cantor M.D.

EmeritusDX

CLIA#: 05D2223424
Medical Director: Sima Fargahi M.D.
12 Spectrum Pointe Drive Lake Forest, CA 92630

Freedom
PATHOLOGY PARTNERS

CLIA#: 39D2071808
Medical Director: Joshua Cantor M.D.
524 E Elm St Conshohocken, PA 19428